Vinge advises Oncorena Holding AB in connection with an investment of initially SEK 66 million from Linc, HealthCap and Fåhraeus Startup and Growth.
The investment will primarily fund Oncorena’s first clinical study, a phase I/II study with orellanine in patients with advanced kidney cancer. In the event that the initial part of the clinical study provides positive results, the investors intend to finance the second part of the study with an additional SEK 94 million.
The Vinge team includes Christian Lindhé, Martin Svanberg and Sofie Nordgren.
